All Topics

The FDA has finalized guidance on clinical investigations for psychedelic drugs, introducing significant changes from its 2023 draft version. Key updates include expanded scope beyond classic psychedelics, heightened focus on functional unblinding and bias mitigation strategies, promotion of innovative trial designs, and emphasis on epidemiological analyses for abuse potential assessments.

The Centers for Medicare & Medicaid Services has proposed sweeping restrictions on Remote Patient Monitoring and Remote Therapeutic Monitoring reimbursement that could fundamentally reshape the telehealth landscape. Will the new direct-employment mandate, initiating visit requirements, and reduced reimbursement rates eliminate existing business models or drive innovation in compliance? Organizations face a critical September 2026 deadline to influence the final rule before January 2027 implementation.

On May 27, 2026, the Superior Court of California held that subdivision (a) of California Penal Code § 638.51 does not apply to software on commercial websites. Plaintiff Brian Blaker sued Defendant NetScout, Inc., alleging the Defendant had violated § 638.51 of the California Invasion of Privacy Act by implementing a software development kit (SDK) on its website.